The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Cardiovascular Genetic Testing Market Over The Period 2026–2030?
The cardiovascular genetic testing market size has seen rapid expansion in recent years. It is anticipated to expand from $3.93 billion in 2025 to $4.35 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This growth observed in previous periods is attributable to heightened awareness of inherited cardiovascular conditions, the enlargement of molecular diagnostic capabilities, the decreasing costs of genetic sequencing, an increase in the utilization of genetic counseling services, and expanded research within cardiovascular genomics.
The cardiovascular genetic testing market size is poised for substantial growth over the upcoming years, with projections indicating it will expand to reach **$6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%**. This anticipated expansion during the forecast period is driven by factors such as a rising need for precision medicine approaches, increasing implementation of population-based genetic screening, the development of AI-driven variant interpretation, greater integration of genomics into clinical decision-making, and a heightened emphasis on preventive cardiovascular healthcare. Prominent trends expected in this period include the wider adoption of predictive genetic risk assessments, an increase in the utilization of multigene panel testing, enhanced incorporation of bioinformatics and AI analytics, the widening scope of pharmacogenomic testing applications, and an intensified focus on customized cardiovascular care.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp
Which Economic Or Industry Drivers Are Impacting The Cardiovascular Genetic Testing Market?
The rising incidence of cardiovascular diseases is anticipated to drive the future expansion of the cardiovascular genetic testing market. Cardiovascular diseases (CVDs) refer to a range of conditions that impact the heart and blood vessels, including ailments such as heart attacks, strokes, and high blood pressure. The escalation in cardiovascular disease prevalence is largely attributed to increasingly sedentary lifestyles linked to urbanization, which contribute to conditions like obesity, hypertension, and various metabolic disorders. This growing frequency of cardiovascular diseases stimulates demand for cardiovascular genetic testing, as identifying genetic risks early allows for tailored prevention and treatment plans to diminish the chances of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Thus, the increasing occurrence of cardiovascular disease is a key factor propelling the growth of the cardiovascular genetic testing market.
How Is The Cardiovascular Genetic Testing Market Divided Into Its Major Segments?
The cardiovascular genetic testing market covered in this report is segmented –
1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types
2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases
3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications
5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing
Subsegments:
1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing
2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing
3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing
4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing
5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing
6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing
How Are Trends Transforming The Cardiovascular Genetic Testing Market Landscape?
Leading companies in the cardiovascular genetic testing market are concentrating on creating innovative solutions, such as clinician-ordered tests, to help ensure medical necessity and tailor testing to a patient’s specific health condition, thereby reducing unnecessary procedures and costs. A clinician-ordered test involves a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient’s health status. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to eight conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets the results and generates patient-friendly reports.
Who Are The Prominent Organizations Shaping The Cardiovascular Genetic Testing Market?
Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.
Read the full cardiovascular genetic testing market report here:
https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report
Which Region Is Anticipated To See The Fastest Growth In The Cardiovascular Genetic Testing Market?
North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cardiovascular Genetic Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33054&type=smp
Browse Through More Reports Similar to the Global Cardiovascular Genetic Testing Market 2026, By The Business Research Company
Cardiovascular Clinical Trials Market Report 2026
Genetic Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report
Direct To Consumer Dtc Genetic Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model